

## Topical Collection

# Neurogenic Neuroinflammation in Fibromyalgia

### Message from the Collection Editors

Chronic pain, fatigue, and depression, all of which are primary fibromyalgia symptoms, have been linked to neuroinflammation in certain regions of the central nervous system. Peripheral and central effects, such as neurogenic neuroinflammation, are also important contributors to the clinical features of each of these disorders. Investigation of the role of neurogenic neuroinflammation in fibromyalgia might contribute to improved understanding of the fundamental mechanisms leading to these enigmatic disorders, as well as to the identification of new therapeutic targets. A major neuroinflammation symptom that has been discovered through research is neurodegeneration. Conditions associated with neuroinflammation include Alzheimer's disease and Parkinson's disease. This collection focuses on the different degrees to which neurogenic neuroinflammation might contribute to the multifactorial pathogenesis of fibromyalgia. Reviews and research articles that discuss novel therapeutic targets and molecular mechanisms involved between the two disorders are welcome.

### Collection Editors

Prof. Dr. Rosanna Di Paola

Department of Veterinary Sciences, University of Messina, Viale SS Annunziata, 98168 Messina, Italy

Dr. Roberta Fusco

Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, 98122 Messina, Italy



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/121796](https://mdpi.com/si/121796)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).